Navigation Links
S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
Date:5/4/2011

SINGAPORE, May 4, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced the restructuring of its collaboration and option agreement with Onyx Pharmaceuticals, which was entered into in January 2009. As a result, S*BIO has regained North American and European rights to its novel JAK2 inhibitors, SB1518 and SB1578, from Onyx.  Following a successful and productive partnership with Onyx, S*BIO will now be in a position to drive the development of its lead JAK2 program independently.

Recent data from Phase 2 clinical trials of SB1518 indicated promising clinical efficacy and good tolerability for the treatment of myelofibrosis (MF), an orphan indication with high unmet medical need.  SB1518 has also demonstrated clinical benefits in patients with relapsed/refractory lymphoma. S*BIO plans to advance SB1518 and SB1578 expeditiously through clinical development, with pivotal trials for SB1518 anticipated to begin later this year.

"Consolidating North American and European rights for SB1518 and SB1578 represents a unique opportunity for S*BIO to steer the global development of these two promising products," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Our strong relationship with Onyx has led to the successful clinical advancement of both SB1518 and SB1578.  SB1518 has now reached a critical inflection point where its future success in a highly competitive field depends on an aggressive and focused development plan. As an existing shareholder, Onyx's interests remain aligned with S*BIO's objective to maximize the value of the JAK2 program and to share in the upside potential of SB1518 and other S*BIO assets."

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around kinases and histone deacetylases (HDAC). SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has now completed Phase 2 trials for MF.  It has received orphan drug designation from the U.S. and the E.U. regulatory authorities. S*BIO's lead HDAC inhibitor, SB939, is currently in Phase 2 trials. S*BIO's SB1317, a novel multikinase inhibitor, is in Phase 1 trials and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. More information about S*BIO can be found at www.sbio.com.S*BIO Pte Ltd:Russo Partners:Hew Yin Chin, Ph.D.

Tony Russo +1 212-845-4251Associate Director, Corporate Development

Tony.Russo@russopartnersllc.com Tel: +65 6827 5000 (Singapore)

Andreas Marathovouniotis +1 212-845-4235yinchin_hew@sbio.com

Andreas.Marathis@russopartnersllc.com
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
3. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... May 5, 2016 Progra m m ... of Oxitec , s mosquito in ... by 96 %   Oxitec ... plan to fight wild Aedes aegypti, the dangerous mosquito that spreads ... island of Grand Cayman .  MRCU, a global leader in ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocythemia Market and ... to their offering.       ... ,The latest research Europe Thrombocythemia Market ... provides comprehensive insights into Thrombocythemia pipeline ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested ... seaweeds. The pair observed that when photosynthetically active radiation (i.e. the white light ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors ... Benefits as the latest addition to its family of Partner Firms. Headquartered in ... compliance, wellness, human resources, and health care consumerism specialists. , “Partnering with UBA ...
(Date:5/5/2016)... ... May 05, 2016 , ... An essential ... U.S. states and certain Canadian provinces is now available from the International Association ... (WCRI). , The report, Workers’ Compensation Laws as of January 1, ...
(Date:5/5/2016)... ... , ... A recent survey by the Midwest Business Group on Health ... and use the free preventive care benefits available to them as part of the ... self-insured public and private employers, MBGH found that only 10% of large employers are ...
(Date:5/5/2016)... TX (PRWEB) , ... May 05, 2016 , ... Vitenas ... AIA/AAH Healthcare Design Awards, presented by the American Institute of Architects and the Academy ... designed by the renowned Perkins+Will and Harrell Architects, opened to patients in October of ...
Breaking Medicine News(10 mins):